On 25 October 2024, Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics announced that it had priced an underwritten offering of 3,642,988 American Depositary Shares (ADSs) representing 3,642,988 new shares at an offering price of USD 5.49 per ADS amounting to gross proceeds of USD 20m. The offering included participation from a new investor HBM Healthcare Investments Ltd, which is a leading healthcare investor, as well as multiple existing investors.
CapLaw Themes
- FinSA (FIDLEG) (32)
- FinIA (FINIG) (11)
- Insurance (8)
- Securities (92)
- Regulatory (128)
- Takeover (19)
- Derivatives (7)
- News, Deals & Cases (450)
- Events (149)
- Other Areas (8)
CapLaw PDF Archive
Discover more articles
We provide up-to-date information on legal and regulatory developments regarding the capital markets, publish concise articles on developments in the Swiss and international financial markets, and announce recent deals and forthcoming events.